The FDA has approved Nayzilam(®)(midazolam) Nasal Spray for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures). The nasal spray is designed as a single-use treatment for patients 12 years and older. It can be carried with a patient and allows for administration by a non-healthcare professional.
UCB, the makers of NAYZILAM, is a global biopharmaceutical company based in Burssels, Belgium. NAYZILAM is the first medication approved to treat seizure clusters in more than 20 years and could provide significant value to patients that have limited treatment options. UCB anticipates NAYZILAM launching in the U.S. later this year. For updates on the availability of NAYZILAM and for more information, visit UCB’s website here.